Results 21 to 30 of about 25,935 (265)
Anti-GD2 immunotherapy for neuroblastoma [PDF]
Expert Review of Anticancer Therapy, 2017 Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.
Sameer, Sait, Shakeel, Modak
openaire +2 more sources
Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas? [PDF]
Journal of Applied Biomedicine, 2021 Cancer stem cells (CSCs) are a theorized subset of cells within the tumor that is thought to drive disease recurrence and metastatic spread. The aim of this study is to investigate mRNA and protein levels of ganglioside GD2 synthase (GD2S), in breast cancer (BC) patients.65 PBMCs of preoperative BC patients without chemotherapy were compared to PBMCs ...
Maryam, Mansoori +8 more
openaire +2 more sources
Biology of GD2 ganglioside: implications for cancer immunotherapy
Frontiers in Pharmacology, 2023 Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide bound to a sialic acid-containing glycan chain, and locate at the plasma membrane.
Pierre Machy +2 more
doaj +1 more source
GD2-Targeted Immunotherapy and Radioimmunotherapy [PDF]
Seminars in Oncology, 2014 Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. They include pediatric embryonal tumors (neuroblastoma, retinoblastoma, brain tumors, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma), as well as adult cancers (small cell lung cancer, melanoma, soft tissue sarcomas).
Konstantin, Dobrenkov +1 more
openaire +2 more sources
GD2 CAR T cells against human glioblastoma [PDF]
npj Precision Oncology, 2021 AbstractGlioblastoma is the most malignant primary brain tumor and is still in need of effective medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 antigen expression representing a potential target for CAR T strategy. Data highlighted a robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with ...
Prapa M. +18 more
openaire +5 more sources
Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/disialoganglioside identify their tumor stem cells. [PDF]
, 2014 IntroductionAlthough breast phyllodes tumors are rare, there is no effective therapy other than surgery. Little is known about their tumor biology.
Chou, Fen-Pi +9 more
core +3 more sources
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine
Pharmaceutics, 2023 Neuroblastoma cells highly express the disialoganglioside GD2, a tumor-associated carbohydrate antigen, which is also expressed in neurons, skin melanocytes, and peripheral nerve fibers.
Lucrezia Galassi +8 more
doaj +1 more source
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]
, 2019 BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena +15 more
core +2 more sources
Cancer, 2001 Neuroblastomas (NBs) almost ubiquitously express the ganglioside GD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular marker of NB.Seventy-seven NB tumor tissues of all stages, 5 NB cell lines, and 26 normal bone marrows (BMs) and peripheral blood (PBL) samples, as well as ...
M S, Lo Piccolo +2 more
openaire +2 more sources
Biosensors, 2023 Neuroblastoma (NB) is known as the “king of childhood tumors” due to its highly metastatic, recurrence-prone, and difficult-to-treat characteristics.
Chong Chen +6 more
doaj +1 more source